NEWS RELEASES

Search all of our news releases here.

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

Dr. Robert R. Redfield Appointed as Special Advisor to the CEO of American Gene Technologies

American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO

Sep 15, 2021

ROCKVILLE, MD. (PRWEB) SEPTEMBER 15, 2021 Dr. Redfield’s expertise in virology strengthens AGT’s capacity to develop innovative HIV treatments. American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of…

Read More
American Gene Technologies announces that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment

HIV Cure Program Releases Initial Clinical Trial Data

Jul 16, 2021

ROCKVILLE, MD, July 15, 2021 /Globe Newswire/ — American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the…

Read More
First Infusion Press Release

AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial

May 27, 2021

ROCKVILLE, MD, May 27, 2021 /PR Newswire/ — American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical trial to evaluate safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore…

Read More
LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases

LGBTQ+ Investment Firm Gaingels Joins American Gene Technologies’ Mission to Cure HIV, and Other Serious Human Diseases

Apr 14, 2021

ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ – American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical…

Read More
The first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease

American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV

Nov 10, 2020

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated…

Read More
American Gene Technologies announces that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Oct 8, 2020

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s…

Read More
American Gene Technologies announces approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program

FDA Approves American Gene Technologies (AGT) To Move Forward With Phase 1 Clinical Trial Of HIV Cure Program

Aug 11, 2020

ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area,…

Read More
Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

Aug 3, 2020

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National…

Read More
American Gene Technologies announces it has leased a spacious, modern facility in the Maryland life sciences corridor, across from National Cancer Institute and Johns Hopkins Shady Grove Campus

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research – Across From National Cancer Institute Campus

Jul 28, 2020

Click on images to view larger ROCKVILLE, Md., July 28, 2020 — American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from…

Read More
American Gene Technologies announces its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston, MA on March 11, 2020

American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston

Mar 10, 2020

ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston,…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Exciting news for the future of medicine! The strategic market insight company Nova 1 values the cell & gene therapy market @ $18 billion in 2023 growing at a CAGR of 18% over the next decade. They see a near $100 billion market size by 2033.loom.ly/kpuPhu4#genetherapy #futureofmedicine ... See MoreSee Less
View on Facebook
This #NYHAAD, we support NYHAAD and their mission to create meaningful and intentional spaces for young people to ask questions, learn, and talk about the impacts of HIV and their community. #StopHIVTogether #EndHIVStigma ... See MoreSee Less
View on Facebook
Listen in with Dr. Marcus Conant as he discusses #genetherapy for HIV suppression with CGTLive here loom.ly/zllWHkQ ... See MoreSee Less
View on Facebook
We are grateful to have Dr. Marcus Conant represent our mission to find a functional cure for #HIV, especially at #CROI2024. Learn about his journey in @PharmaVoice: loom.ly/JV88YD0 ... See MoreSee Less
View on Facebook